Table 1 Study characteristics of included studies

Andorsky 2019 [23]

US

2019

Idelalisib

Retrospective cohort study

54

18.6

0.6–49.5

Assouline 2020 [32]

US, Australia, South Korea, Canada, Europe

2020

Mosunetuzumab

Phase I trial

62

14.4

–

Batlevi 2020 [7]

US

2020

Representative cohort

Retrospective cohort study

299

87.6

2.4–200.4

CHRONOS 1 part B [33]

Europe, Asia, US, Australia, New Zealand

2017

Copanlisib

Phase II trial

104

6.69

0.23–24.01

DAWN [34]

Europe, Asia, US, South America, Australia

2018

Ibrutinib

Phase II trial

110

27.7

1.1–37.1

DELTA [24]

Europe, US

2014

Idelalisib

Phase II trial

72

33.9

1.2–81.4

ELM-1 [21]

Europe, US, Canada, Australia, Asia

2020

Odronextamab

Phase I trial

28

6.8

1.0–22.1

Evens 2013 [43]

US

2013

Allo-SCT

Prospective cohort study

184

48

N/R

EZH [35]

Europe, US, Canada, Australia, Taiwan

2018

Tazemetostat

Phase II trial

99

N/R

N/R

Fuji 2020 [19]

Japan

2020

Representative cohort

Retrospective cohort study

41

89.64

28.56–134.40

Ito 2013 [39]

Japan

2013

Allo-SCT

Retrospective cohort study

30

21.4

0.4–165.4

Khouri 2008 [36]

US

2008

Allo-SCT

Phase II trial

47

107

72–142

Laport 2016 [37]

US

2016

Allo-SCT, Auto SCT

Phase II trial

62

47

30–73

Link 2019 [20]

US

2019

Representative cohort

Prospective cohort study

438

96

0.24–124.8

Lunning 2016 [40]

US

2016

Auto-SCT

Retrospective cohort study

44

60

21.8–96

Muntanola 2020 [22]

Spain

2020

R-ESHAP

Retrospective cohort study

28

N/R

N/R

Robert 2019 [25]

France

2019

Idelalisib

Retrospective cohort study

24

23

20–24

Sesques 2020 [41]

France

2020

Auto-SCT

Retrospective cohort study

61

105.6

27.6–291.6

UNITY-NHL [38]

Europe, US, Australia, Korea

2021

Umbralisib

Phase II trial

117

27.5

20.9–37.1

Vose 2008 [42]

US

2008

Auto-SCT

Retrospective cohort study

108

72

12–192